Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Ovarian Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 24Paclitaxel 11Carboplatin 11Trastuzumab 9Nivolumab 7Fulvestrant 6palbociclib 4olaparib 4Taxes 4Surveys and Questionnaires 4Methods 4Early Intervention, Educational 4Docetaxel 4Cyclophosphamide 4Biopsy 4Bevacizumab 4pertuzumab 3lenvatinib 3fludarabine 3atezolizumab 3abemaciclib 3Tamoxifen 3Specimen Handling 3Psychiatric Rehabilitation 3Metformin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interviews as Topic 3Gemcitabine 3Counseling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × rebastinib × Breast × Clear all
NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
177 enrolled 25 charts
BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡